Join to View Full Profile
3730 S Eastern AveLas Vegas, NV 89169
Phone+1 702-952-3400
Fax+1 702-952-3461
Dr. Braiteh is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine, 2000 - 2003
St Joseph's University Medical SchoolClass of 1998
Certifications & Licensure
OH State Medical License Current
NV State Medical License 2010 - 2027
TX State Medical License 2004 - 2027
MI State Medical License 2009 - 2013
CT State Medical License 2003 - 2004
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification iKnowMed EHR, McKesson, 2013-2017
- CMS Meaningful Use Stage 2 Certification iKnowMed EHR, McKesson, 2013-2017
- Vegas Seven Castle Connolly, 2014
Clinical Trials
- A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
- Safety Study of PLX108-01 in Patients With Solid Tumors Start of enrollment: 2009 Oct 01
- A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Publications & Presentations
PubMed
- Exploring decisional control preferences in older patients with cancer and their caregivers.Sofiia Hryniv, Elizabeth Gilbride, William Consagra, Supriya Mohile, Sule Yilmaz
Journal of Geriatric Oncology. 2025-12-12 - 42 citationsAutogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.Juanita Lopez, Thomas Powles, Fadi Braiteh, Lillian L Siu, Patricia LoRusso
Nature Medicine. 2025-01-01 - 4 citationsPhase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.Shubham Pant, Erika Hamilton, Susanna V Ulahannan, James F Strauss, Fadi S Braiteh
Cancer. 2023-06-15
Journal Articles
- Oxford University Press Has Registered This DOI Pre-PublicationFadi Braiteh, MD, Oxford University Press
Press Mentions
Nab-Paclitaxel plus Gemcitabine Opens up Treatment Options in Pancreatic CancerMarch 16th, 2016
Nab-Paclitaxel Outduels Paclitaxel in HR+/HER2- and Triple-Negative MBCMarch 12th, 2016
US Oncology Research Translational Oncology Program Enrolls 2,000February 4th, 2016
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
